ADMA BIOLOGICS, INC. Payments of Stock Issuance Costs
ADMA BIOLOGICS, INC. (ADMA) reported Payments of Stock Issuance Costs of $1.24 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-24.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2017-02-24
- ADMA BIOLOGICS, INC. payments of stock issuance costs for the quarter ending 2016-12-31 was $0.00.
- ADMA BIOLOGICS, INC. payments of stock issuance costs for the quarter ending 2015-12-31 was $0.00.
- ADMA BIOLOGICS, INC. payments of stock issuance costs for the quarter ending 2015-09-30 was $0.00, a 100.00% decline year-over-year.
- ADMA BIOLOGICS, INC. payments of stock issuance costs for the quarter ending 2014-12-31 was -$42.54K, a 111.88% decline year-over-year.
- ADMA BIOLOGICS, INC. payments of stock issuance costs for fiscal 2016 was $1.24M.
- ADMA BIOLOGICS, INC. payments of stock issuance costs for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- ADMA BIOLOGICS, INC. payments of stock issuance costs for fiscal 2014 was $12.00K, a 96.89% decline from fiscal 2013.
- ADMA BIOLOGICS, INC. payments of stock issuance costs for fiscal 2013 was $386.47K, a 71.12% decline from fiscal 2012.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | $1.24M 10-K · filed 2017-02-24 | ||
| 2016-09-30 | $1.24M 10-Q · filed 2016-11-10 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | $0.00 derived: sum of 2 quarters · filed 2017-02-24 | $0.00 10-K · filed 2017-02-24 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $0.00 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-11 | |||
| 2014-12-31 | -$42.54K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $3.37K derived: sum of 2 quarters · filed 2016-03-23 | $12.00K 10-K · filed 2016-03-23 | |
| 2014-09-30 | $45.92K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $54.54K 10-Q · filed 2015-11-10 | ||
| 2014-06-30 | $8.63K 10-Q · filed 2015-08-11 | |||
| 2013-12-31 | $357.99K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $386.47K 10-K · filed 2015-03-09 | ||
| 2013-09-30 | $28.48K 10-Q · filed 2014-11-10 | |||
| 2013-03-31 | $71.51K 10-Q · filed 2014-05-12 | $143.03K derived: sum of 2 quarters · filed 2014-05-12 | $179.17K derived: sum of 3 quarters · filed 2014-05-12 | $475.57K derived: sum of 4 quarters · filed 2014-05-12 |
| 2012-12-31 | $71.51K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-28 | $107.65K derived: sum of 2 quarters · filed 2014-03-28 | $404.05K derived: sum of 3 quarters · filed 2014-03-28 | $1.34M 10-K · filed 2014-03-28 |
| 2012-09-30 | $36.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $332.54K derived: sum of 2 quarters · filed 2013-11-12 | $1.27M 10-Q · filed 2013-11-12 | $1.27M derived: sum of 4 quarters · filed 2013-11-12 |
| 2012-06-30 | $296.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-12 | $1.23M 10-Q · filed 2013-08-12 | $1.23M derived: sum of 3 quarters · filed 2013-08-12 | |
| 2012-03-31 | $933.96K 10-Q · filed 2013-05-14 | $933.96K derived: sum of 2 quarters · filed 2013-05-14 | ||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-06 | $0.00 10-K · filed 2013-03-06 | ||
| 2011-09-30 | $0.00 10-Q · filed 2012-11-13 | |||
| 2011-03-31 | $0.00 10-Q · filed 2012-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |